Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

s in Huntington's disease if the

results of the ongoing Phase 2 clinical trial are supportive.

-- Report additional follow-up data from the first pivotal trial of

Dimebon in AD.

-- Report data on Dimebon's novel mechanism of action.

-- Complete the ongoing Phase 1-2 clinical trial of MDV3100 in HRPC.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation's preclinical and clinical data, so its views remain subject to change. Medivation's filings with the Securities and Exchange Commission, including its Annual Repor
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Whitehouse Laboratories is pleased ... Morris County (New Jersey) Chamber of Commerce as ... business organization in the North Jersey area, offers ... some key clients in the pharmaceutical and biotechnology ... area. Membership enables Whitehouse Laboratories a higher level ...
(Date:11/26/2014)... The Pittcon marketing department is pleased to announce ... app, Pittcon 2015 . The ... for iOS and Android devices and the Kindle Fire, ... after the event. It acts as an all-inclusive real-time ... Conferee Networking sessions and short courses. , The Pittcon ...
(Date:11/26/2014)... November 26, 2014 CURE™ magazine ... reception on December 5, 2014, in San Francisco prior ... MPN Heroes event will honor clinicians, caregivers, and advocates ... myeloproliferative neoplasms (MPNs). , Special guest speaker Charles ... family's cancer journey at the reception. Over a ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... developed a device platform that combines electronic components for ... an ultrathin skin-like patch that mounts directly onto the ... temporary tattoo. Led by researcher John A. Rogers, ... University of Illinois, the researchers described their novel skin-mounted ...
... Neb., Aug. 11, 2011 Transgenomic, Inc. (OTC/BB: TBIO) today ... June 30, 2011 and provided a business update. Second ... were $7.7 million, an increase of 50 percent compared with ... was $4.6 million or 59 percent of net sales, compared ...
... Inc. (Nasdaq: GNVC ) today announced that its ... Rights Plan through the adoption of a new Rights Agreement. ... September 7, 2011, which is the date that GenVec,s existing ... was adopted in connection with the expiration of the existing ...
Cached Biology Technology:Smart skin: Electronics that stick and stretch like a temporary tattoo 2Smart skin: Electronics that stick and stretch like a temporary tattoo 3Transgenomic Reports Second Quarter Financial Results 2Transgenomic Reports Second Quarter Financial Results 3Transgenomic Reports Second Quarter Financial Results 4Transgenomic Reports Second Quarter Financial Results 5Transgenomic Reports Second Quarter Financial Results 6Transgenomic Reports Second Quarter Financial Results 7Transgenomic Reports Second Quarter Financial Results 8Transgenomic Reports Second Quarter Financial Results 9GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... 1:00 p.m. ET) Research published in Nature Chemical Biology ... pathway, termed necroptosis, all target and inhibit RIP1 kinase, ... by trauma such as a heart attack or stroke, ... damage contributing to death or long-term disability. The findings ...
... nuts included in a heart healthy diet reduced low-density ... with qualified health claims, according to researchers. "We looked ... in the health claim for tree nuts, while other ... heart healthy diet," says Dr. Amy E. Griel, a ...
... the mid-1970s, Glenn Shaw of the Geophysical Institute at ... of Arctic haze after collecting aerosol samples from Barrow, ... contain relatively pure air due to its remote locale ... Shaws data indicated there was a murky cloud of ...
Cached Biology News:Stopping unwanted cell death: Implications for drug discovery 2Stopping unwanted cell death: Implications for drug discovery 3Macadamia nuts can be included in heart healthy diet 2Atmospheric scientists gear up for collaborative airborne campaigns 2
... the gap between the 500 l and ... the speed of the classic Vivaspin products ... for superior recoveries from very dilute solutions. ... Cellulose Triacetate membranes, Vivaspin 2 offers the ...
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
Goat polyclonal to Lipocalin 2...
... (VMAT2). An antibody made to the C-terminal ... ~55 kDa in postnuclear supernatants of CHO ... type cells (2). Some additional bands, both ... detected and remain unaffected by the inclusion ...
Biology Products: